• Explore /
  • Poster
  • / BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first‑line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062).

BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first‑line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062).

Abstract Video & Slides Poster

Authors

null

Peter Schmid

Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Peter Schmid , Ana Tablante Nunes , Hannah Dry , Rachel Dougherty , Vatsala Karwe , Urban J. Scheuring

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT03742102

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS1105)

DOI

10.1200/JCO.2021.39.15_suppl.TPS1105

Abstract #

TPS1105

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Peter Schmid

First Author: Yelena Y. Janjigian

First Author: Hossein Borghaei

First Author: Yung-Jue Bang